argenx reports positive phase 3 ADAPT SERON results of VYVGART in AChR-Ab seronegative gMG
VYVGART was well tolerated, with a safety profile consistent with prior studies in AChR-Ab seropositive gMG and other indications
VYVGART was well tolerated, with a safety profile consistent with prior studies in AChR-Ab seropositive gMG and other indications
Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks
Subscribe To Our Newsletter & Stay Updated